Pathobiology of secondary immune thrombocytopenia.

Abstract:

:Primary immune thrombocytopenic purpura (ITP) remains a diagnosis of exclusion both from nonimmune causes of thrombocytopenia and immune thrombocytopenia that develops in the context of other disorders (secondary immune thrombocytopenia). The pathobiology, natural history, and response to therapy of the diverse causes of secondary ITP differ from each other and from primary ITP, so accurate diagnosis is essential. Immune thrombocytopenia can be secondary to medications or to a concurrent disease, such as an autoimmune condition (eg, systemic lupus erythematosus [SLE], antiphospholipid antibody syndrome [APS], immune thyroid disease, or Evans syndrome), a lymphoproliferative disease (eg, chronic lymphocytic leukemia or large granular T-lymphocyte lymphocytic leukemia), or chronic infection, eg, with Helicobacter pylori, human immunodeficiency virus (HIV), or hepatitis C virus (HCV). Response to infection may generate antibodies that cross-react with platelet antigens (HIV, H pylori) or immune complexes that bind to platelet Fcgamma receptors (HCV), and platelet production may be impaired by infection of megakaryocyte (MK) bone marrow-dependent progenitor cells (HCV and HIV), decreased production of thrombopoietin (TPO), and splenic sequestration of platelets secondary to portal hypertension (HCV). Sudden and severe onset of thrombocytopenia has been observed in children after vaccination for measles, mumps, and rubella or natural viral infections, including Epstein-Barr virus, cytomegalovirus, and varicella zoster virus. This thrombocytopenia may be caused by cross-reacting antibodies and closely mimics acute ITP of childhood. Proper diagnosis and treatment of the underlying disorder, where necessary, play an important role in patient management.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Cines DB,Liebman H,Stasi R

doi

10.1053/j.seminhematol.2008.12.005

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

S2-14

issue

1 Suppl 2

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(08)00204-7

journal_volume

46

pub_type

杂志文章,评审
  • Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract::Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.36927

    authors: Hoelzer D,Gökbuget N,Ottmann OG

    更新日期:2002-10-01 00:00:00

  • Further understanding of recombinant activated factor VII mode of action.

    abstract::Recombinant activated factor VII (rFVIIa) is being increasingly used to treat bleeding associated with a variety of non-hemophilic coagulopathic indications, and its mechanism of action in these areas is under active investigation. Numerous studies have shown that FVIIa binds with low affinity to activated platelets; ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.03.013

    authors: Monroe DM

    更新日期:2008-04-01 00:00:00

  • Screening for hemochromatosis: phenotype versus genotype.

    abstract::Hereditary hemochromatosis is one of the most common inherited disorders among Caucasians of European ancestry. Malregulation of iron absorption from the duodenum eventually leads to iron overload. Although the time required to become iron loaded is variable, it is clear that most homozygotes will eventually become sy...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Edwards CQ,Griffen LM,Ajioka RS,Kushner JP

    更新日期:1998-01-01 00:00:00

  • Structural and functional characterization of B-domain deleted recombinant factor VIII.

    abstract::A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90103-9

    authors: Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

    更新日期:2001-04-01 00:00:00

  • Control of late neutrophil-specific gene expression: insights into regulation of myeloid differentiation.

    abstract::During myeloid differentiation, the pluripotent hematopoietic stem cell passes through several well-defined morphologic stages within the bone marrow. These changes include progressive nuclear segmentation and the acquisition of stage-specific granules. Primary granules appear at the myeloblast stage, and are found in...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Sigurdsson F,Khanna-Gupta A,Lawson N,Berliner N

    更新日期:1997-10-01 00:00:00

  • Transplant decision-making strategies in the myeloproliferative disorders.

    abstract::Myelofibrosis with myeloid metaplasia, also known as idiopathic myelofibrosis (IF) or agnogenic myeloid metaplasia, is one of the characteristic manifestations of polycythemia vera (PV) in the spent phase, and has a particularly adverse prognosis. IF may also present de novo. To date, treatment strategies for both spe...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50032

    authors: Fruchtman SM

    更新日期:2003-01-01 00:00:00

  • Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura.

    abstract::Idiopathic thrombocytopenic purpura (ITP) is an illness of primary acquired thrombocytopenia occurring in the absence of marrow failure. Splenectomy was first used as a treatment for ITP in 1913. However, with the realization that opsonin (critical for the optimal killing of invasive micro-organisms by white blood cel...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90114-8

    authors: Bell WR Jr

    更新日期:2000-01-01 00:00:00

  • Proteasome inhibition for antibody-mediated allograft rejection.

    abstract::Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2012.04.008

    authors: Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

    更新日期:2012-07-01 00:00:00

  • Monitoring inhibitor patients with the right assays.

    abstract::The inhibitor titer is the most important clinical measurement in inhibitor patients, and the Nijmegen method is preferable to the original and well-established Bethesda assay for this purpose; however, both methods have high inter-laboratory variability. Monitoring inhibitor patients after treatment with bypassing ag...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.03.002

    authors: Barrowcliffe TW

    更新日期:2008-04-01 00:00:00

  • Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment.

    abstract::Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.024

    authors: Ingerslev J,Hvid I

    更新日期:2006-01-01 00:00:00

  • Mantle-cell lymphoma.

    abstract::Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blasti...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Campo E,Raffeld M,Jaffe ES

    更新日期:1999-04-01 00:00:00

  • Thrombopoietin receptor agonists in primary immune thrombocytopenia.

    abstract::Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO recepto...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.005

    authors: Siegal D,Crowther M,Cuker A

    更新日期:2013-01-01 00:00:00

  • Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

    abstract::Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.06.003

    authors: Talati C,Sallman D,List A

    更新日期:2017-07-01 00:00:00

  • Coombs--negative immune hemolytic anemia.

    abstract::An immune hemolytic anemia occurs in a few patients in whom the concentration of antibody on the red cell is below the level for detection by the usual antiglobulin test. Clinically, these patients are identical to patients with warm type Coombs-positive hemolytic anemia, except for the quantity of antibody on the cel...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Gilliland BC

    更新日期:1976-10-01 00:00:00

  • High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.

    abstract::The use of combination chemotherapy has been successful in treating advanced or widespread Hodgkin's disease (HD). For patients with relapsed disease, the long-term prognosis is much poorer, despite the good rate of reinduction into a second or further remission using conventional treatments. The majority of such pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Laurence AD,Goldstone AH

    更新日期:1999-07-01 00:00:00

  • Clinical evaluation of iron deficiency.

    abstract::While the prevalence of iron deficiency has remained relatively constant, there has been continuing refinement in its laboratory recognition, especially with the recent introduction of serum ferritin and FEP measurements. It is helpful to classify iron deficiency into three stages. Storage iron depletion is identified...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Cook JD

    更新日期:1982-01-01 00:00:00

  • Limitations of conventional treatment options for heparin-induced thrombocytopenia.

    abstract::Thrombosis is a common and potentially serious complication of immune-mediated heparin-induced thrombocytopenia (HIT). Discontinuation of heparin is a simple and important maneuver in patients with suspected HIT. Unfortunately, thrombosis often occurs even in those patients in whom heparin was discontinued because of ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Warkentin TE

    更新日期:1998-10-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • The Kell blood group system: Kell and XK membrane proteins.

    abstract::Two membrane proteins express the antigens that comprise the Kell blood group system. A single antigen, Kx, is carried on XK, a 440-amino acid protein that spans the membrane 10 times, and more than 20 antigens reside on Kell, a 93-kd, type II glycoprotein. XK and Kell are linked, close to the membrane surface, by a s...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90036-2

    authors: Lee S,Russo D,Redman CM

    更新日期:2000-04-01 00:00:00

  • Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.

    abstract::The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Tefferi A

    更新日期:1999-01-01 00:00:00

  • Mismatched unrelated alternative donors for hematological malignancies.

    abstract::For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.01.009

    authors: Sebastian Schäfer H,Finke J

    更新日期:2016-04-01 00:00:00

  • Treatment strategies for Hodgkin's disease.

    abstract::Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonadonna G,Santoro A,Viviani S,Valagussa P

    更新日期:1988-04-01 00:00:00

  • RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).

    abstract::In this review, we discuss disease-causing alterations of RUNT-related transcription factor 1 (RUNX1), a master regulator of hematopoietic differentiation. Familial platelet disorder with predisposition to myeloid leukemia (FPDMM) typically presents with (1) mild to moderate thrombocytopenia with normal-sized platelet...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.04.006

    authors: Schlegelberger B,Heller PG

    更新日期:2017-04-01 00:00:00

  • The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.

    abstract::Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Glaspy J

    更新日期:1997-07-01 00:00:00

  • Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation.

    abstract::Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.009

    authors: Fuji S,Kapp M,Einsele H

    更新日期:2012-01-01 00:00:00

  • Cobalamin deficiency in patients infected with the human immunodeficiency virus.

    abstract::Serum vitamin B12 levels are often low in human immunodeficiency virus (HIV)-infected patients. However, only a few patients appear to have actual vitamin B12 deficiency. A low red cell folate level accompanying the low vitamin B12 level makes the presence of vitamin B12 deficiency more likely. Our experience suggests...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Remacha AF,Cadafalch J

    更新日期:1999-01-01 00:00:00

  • New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

    abstract::Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.023

    authors: Ng HJ,Crowther MA

    更新日期:2006-01-01 00:00:00

  • Decitabine dosing schedules.

    abstract::5-Aza-2'-deoxycytidine (decitabine; Dacogen, MGI Pharma, Inc, Bloomington, MN) is a cytidine analog that inhibits DNA methyltransferases resulting in loss of DNA methylation with subsequent gene re-expression. This compound was first synthesized over 40 years ago and since that time much information has been learned r...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.05.006

    authors: Kantarjian HM,Issa JP

    更新日期:2005-07-01 00:00:00

  • Monoclonal antibodies in lymphoma: the first decade.

    abstract::The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has sign...

    journal_title:Seminars in hematology

    pub_type:

    doi:10.1053/j.seminhematol.2008.02.005

    authors: Link BK,Friedberg JW

    更新日期:2008-04-01 00:00:00

  • Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

    abstract::Acute myeloid leukemia (AML) is a heterogeneous disease characterized by multiple genetic and epigenetic alterations. The major causes of treatment failure remain disease relapse and treatment toxicity. However, major advances in biological determinants of disease relapse, development of targeted molecules, improvemen...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2015.03.001

    authors: Brissot E,Mohty M

    更新日期:2015-07-01 00:00:00